AstraZeneca

Meissa Vaccines Inc is a biotechnology company based in Redwood City, CA, dedicated to developing live attenuated vaccines for respiratory viruses such as RSV and COVID-19. Their innovative technologies, including the proprietary AttenuBlock platform, aim to deliver effective vaccines globally, preventing infection and generating a strong immune response. With a mission to safeguard people worldwide from life-threatening respiratory viruses, Meissa Vaccines focuses on developing safe and highly attenuated vaccine candidates that induce a better immune response than natural infection. Their RSV and COVID-19 vaccine candidates are designed to provide a durable immune response by stimulating mucosal IgA and serum neutralizing antibodies.Generated from the website

Structure Therapeutics Inc is a biotechnology company based in South San Francisco, CA, focused on innovative therapeutic approaches. The company is dedicated to advancing its pipeline of drug candidates aimed at addressing unmet medical needs. With a team of experienced professionals, Structure Therapeutics emphasizes collaboration and cutting-edge research in the development of its therapies. Their commitment to scientific excellence drives their mission to improve patient outcomes through novel treatments. Generated from the website

Pionyr Immunotherapeutics, Inc., a biotechnology company based in South San Francisco, CA, was acquired by Ikena Oncology, Inc. in August 2023. Their innovative Myeloid Tuning programs aim to enhance the immune system's anti-tumor response by modifying the cellular infiltrate of the tumor microenvironment. With clinical programs targeting TREM2 and TREM1, Pionyr focuses on selectively depleting and reprogramming tumor-associated macrophages responsible for immunosuppression, demonstrating safety in Phase 1a b trials alone and in combination with pembrolizumab. Additionally, their IND-ready program, PY265 anti-MARCO, aims to activate the immune system in the tumor microenvironment. Pionyr Immunotherapeutics has made significant contributions to the field of immunotherapy, as evidenced by their posters, publications, and whitepapers. As part of Ikena Oncology, the company's business development team is open to discussions regarding licensing and partnerships for their pioneering programs. With a commitment to advancing cancer treatment, Pionyr Immunotherapeutics continues to make strides in developing novel therapies to combat tumors and improve patient outcomes.Generated from the website